President Donald Trump announced nine new drug companies joined his pricing plan on Monday in the Oval Office. This move brings the total to 26 firms that now cover 89 percent of the branded drug market. The new partners include Alcon, Astellas Pharma, and Teva Pharmaceuticals among others. Each company agreed to match the low prices they charge in other developed nations.
Health and Human Services Secretary Robert F. Kennedy Jr. highlighted the scope of the new agreements. He declared that 26 companies have now reached agreements with us. Nine out of ten drugs Americans use are covered by these agreements, per RedState. The deals target high costs for common medicines used by millions of families.
.@POTUS announces a major expansion of his Most Favored Nation drug pricing initiative — with nine new pharmaceutical companies committing to deliver their lowest drug prices for American patients. pic.twitter.com/hNoPACjnVk
— Rapid Response 47 (@RapidResponse47) August 31, 2026
Trump called the expansion a major win for affordability during the announcement. He said, “Nine new pharmaceutical companies are committing to deliver their lowest drug prices for American patients,” according to Breitbart. These new agreements ensure that state Medicaid programs can access these much lower prices immediately.
The new partners also promised to invest a massive amount of money back into U.S. manufacturing. According to reports, these nine firms committed at least $19.6 billion for new production facilities. Some companies are even donating thousands of tons of vital ingredients to a national reserve.
Sun Pharma will provide 71.4 tons of clindamycin and 6.75 tons of doxycycline to the reserve. Teva Pharmaceuticals agreed to donate 45 metric tons of metronidazole and 4.8 tons of amlodipine. Levetiracetam, a vital seizure prevention medication for patients, will be supplied by UCB in an amount of 163 tons.
.@SecKennedy: “Today brings us to a total of 26 companies that have now made agreements with us. These agreements cover nine out of ten drugs that are used by Americans.” https://t.co/sy3VxBS1jF pic.twitter.com/fQMMRO9sdu
— Rapid Response 47 (@RapidResponse47) August 31, 2026
The program covers treatments for serious conditions like Parkinson’s disease and various forms of cancer. The deals lower costs on drugs for hemophilia and macular degeneration too. All new medicines these companies launch will also fall under the same low-price framework.
Trump has used the threat of tariffs to pressure manufacturers to close the price gap. Compared to other nations, patients in the U.S. currently pay almost three times the price. This latest batch of deals shows that the pressure is working to bring costs down.
The 26 companies now include major names like Eli Lilly, Merck, and Johnson & Johnson. These firms represent nearly 90 percent of the entire branded drug market in the United States. The agreements mark the 18th through 26th deals secured since last fall.
This push changes how American families pay for the medicines they need every day. These actions are projected to save billions of dollars for Americans nationwide. The focus remains on keeping essential drugs affordable for everyone who needs them.
